Biomarkers associated with migraine and their potential role in migraine management

Headache

Volumn 53, Issue 8, 2013, Pages 1262-1277

  Durham, Paul ^a   Papapetropoulos, Spyros ^b  

^a MISSOURI STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

biological marker; chronic migraine; disease pathophysiology

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMITRIPTYLINE; BIOLOGICAL MARKER; CALCITONIN GENE RELATED PEPTIDE; CYTOCHROME P450 1A2; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; FLUNARIZINE; GLUTATHIONE TRANSFERASE; MOLECULAR MARKER; NAPROXEN; NEUROKININ A; OREXIN 1 RECEPTOR; PROPRANOLOL; PROSTAGLANDIN DERIVATIVE; RIZATRIPTAN; SUMATRIPTAN; SYNTAXIN 1A; TOPIRAMATE; TRIPTAN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; EPISODIC MIGRAINE; FAMILIAL HEMIPLEGIC MIGRAINE; GENETIC ASSOCIATION; HUMAN; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; TENSION HEADACHE; TRANSFORMED MIGRAINE;

BIOLOGICAL MARKER; CHRONIC MIGRAINE; DISEASE PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MANAGEMENT; HUMANS; INFLAMMATION MEDIATORS; MIGRAINE DISORDERS; MUTATION; TRIGEMINAL NERVE;

EID: 84884143642     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12174     Document Type: Article

References (107)

1. Haut SR, Bigal ME, Lipton RB,. Chronic disorders with episodic manifestations: Focus on epilepsy and migraine. Lancet Neurol. 2006; 5: 148-157.
2. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
3. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB,. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010; 52: 8-14.
4. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010; 30: 599-609.
5. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011; 31: 301-315.
6. Pietrobon D,. Migraine: New molecular mechanisms. Neuroscientist. 2005; 11: 373-386.
7. Pietrobon D, Striessnig J,. Neurobiology of migraine. Nat Rev Neurosci. 2003; 4: 386-398.
8. Vecchia D, Pietrobon D,. Migraine: A disorder of brain excitatory-inhibitory balance? Trends Neurosci. 2012; 35: 507-520.
9. Dalkara T, Nozari A, Moskowitz MA,. Migraine aura pathophysiology: The role of blood vessels and microembolisation. Lancet Neurol. 2010; 9: 309-317.
10. Sprenger T, Goadsby PJ,. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009; 7: 71.
11. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ,. Clinical relevance of cortical spreading depression in neurological disorders: Migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab. 2011; 31: 17-35.
12. Loder E, Rizzoli P,. Biomarkers in migraine: Their promise, problems, and practical applications. Headache. 2006; 46: 1046-1058.
13. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95.
14. Phillips KA, Van BS, Issa AM,. Diagnostics and biomarker development: Priming the pipeline. Nat Rev Drug Discov. 2006; 5: 463-469.
15. Riely GJ, Marks J, Pao W,. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009; 6: 201-205.
16. Chan D, Ng LL,. Biomarkers in acute myocardial infarction. BMC Med. 2010; 8: 34.
17. McDonnell B, Hearty S, Leonard P, O'Kennedy R,. Cardiac biomarkers and the case for point-of-care testing. Clin Biochem. 2009; 42: 549-561.
18. Borsook D, Becerra L, Hargreaves R,. Biomarkers for chronic pain and analgesia. Part 1: The need, reality, challenges, and solutions. Discov Med. 2011; 11: 197-207.
19. Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007; 130: 346-356.
20. Chasman DI, Schurks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011; 43: 695-698.
21. Freilinger T, Anttila V, de Vries B, et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet. 2012; 44: 777-782.
22. Cutrer FM, Black DF,. Imaging findings of migraine. Headache. 2006; 46: 1095-1107.
23. Del ZM, Cherchi A, Palmas MA, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998; 51: 781-786.
24. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet. 2009; 125: 265-279.
25. Maude S, Curtin J, Breen G, et al. The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. Psychiatr Genet. 2001; 11: 49-52.
26. Rebaudengo N, Rainero I, Parziale A, et al. Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. Cephalalgia. 2004; 24: 503-507.
27. Weiss JN, Karma A, MacLellan WR, et al. "Good enough solutions" and the genetics of complex diseases. Circ Res. 2012; 111: 493-504.
28. Carlsson A, Forsgren L, Nylander PO, et al. Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology. 2002; 59: 1804-1807.
29. Oterino A, Toriello M, Valle N, et al. The relationship between homocysteine and genes of folate-related enzymes in migraine patients. Headache. 2010; 50: 99-168.
30. Guzik TJ, Mangalat D, Korbut R,. Adipocytokines-Novel link between inflammation and vascular function? J Physiol Pharmacol. 2006; 57: 505-528.
31. Bockowski L, Sobaniec W, Zelazowska-Rutkowska B,. Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol. 2009; 41: 17-21.
32. Kacinski M, Gergont A, Kubik A, Steczkowska-Klucznik M,. Proinflammatory cytokines in children with migraine with or without aura. Przegl Lek. 2005; 62: 1276-1280.
33. Sarchielli P, Alberti A, Baldi A, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006; 46: 200-207.
34. Perini F, D'Andrea G, Galloni E, et al. Plasma cytokine levels in migraineurs and controls. Headache. 2005; 45: 926-931.
35. Naya M, Tsukamoto T, Morita K, et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res. 2007; 30: 541-548.
36. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006; 99: 69-77.
37. Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM,. Vascular risk factors, endothelial function, and carotid thickness in patients with migraine: Relationship to atherosclerosis. J Stroke Cerebrovasc Dis. 2010; 19: 92-103.
38. Rossato A, Veronese F, Maggioni F, et al. Autonomic dysfunction and endothelial changes in migraine sufferers. Panminerva Med. 2011; 53: 13-18.
39. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA,. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009; 40: 2977-2982.
40. Vanmolkot FH, de Hoon JN,. Endothelial function in migraine: A cross-sectional study. BMC Neurol. 2010; 10: 119.
41. Perko D, Pretnar-Oblak J, Sabovic M, Zvan B, Zaletel M,. Endothelium-dependent vasodilatation in migraine patients. Cephalalgia. 2011; 31: 654-660.
42. Nelson KB, Richardson AK, He J, Lateef TM, Khoromi S, Merikangas KR,. Headache and biomarkers predictive of vascular disease in a representative sample of US children. Arch Pediatr Adolesc Med. 2010; 164: 358-362.
43. Lim CS, Shalhoub J, Gohel MS, Shepherd AC, Davies AH,. Matrix metalloproteinases in vascular disease-A potential therapeutic target? Curr Vasc Pharmacol. 2010; 8: 75-85.
44. Imamura K, Takeshima T, Fusayasu E, Nakashima K,. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 2008; 48: 135-139.
45. Edvinsson L, Ho TW,. CGRP receptor antagonism and migraine. Neurother. 2010; 7: 164-175.
46. Bellamy JL, Cady RK, Durham PL,. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache. 2006; 46: 24-33.
47. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J,. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000; 86: 133-138.
48. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL,. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009; 49: 1258-1266.
49. Vause CV, Durham PL,. Identification of cytokines and signaling proteins differentially regulated by sumatriptan/naproxen. Headache. 2012; 52: 80-89.
50. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW,. Serotonin metabolism in migraine. Neurology. 1989; 39: 1239-1242.
51. Gagnier JJ,. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev. 2001; 6: 383-389.
52. Masruha MR, Vieira DS, Minett TS, et al. Low urinary 6- sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008; 9: 221-224.
53. Masruha MR, Lin J, Vieira DS, et al. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache. 2010; 50: 413-419.
54. D'Andrea G, Granella F, Perini F, Farruggio A, Leone M, Bussone G,. Platelet levels of dopamine are increased in migraine and cluster headache. Headache. 2006; 46: 585-591.
55. Sarchielli P, Gallai V,. Nerve growth factor and chronic daily headache: A potential implication for therapy. Expert Rev Neurother. 2004; 4: 115-127.
56. Jang MU, Park JW, Kho HS, Chung SC, Chung JW,. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral Dis. 2011; 17: 187-193.
57. Ishizaki K, Takeshima T, Fukuhara Y, et al. Increased plasma transforming growth factor-beta1 in migraine. Headache. 2005; 45: 1224-1228.
58. Guldiken B, Guldiken S, Demir M, Turgut N, Tugrul A,. Low leptin levels in migraine: A case control study. Headache. 2008; 48: 1103-1107.
59. Rist PM, Tzourio C, Kurth T,. Associations between lipid levels and migraine: Cross-sectional analysis in the epidemiology of vascular ageing study. Cephalalgia. 2011; 31: 1459-1465.
60. Durham PL, Vause CV, Derosier F, McDonald S, Cady R, Martin V,. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache. 2010; 50: 844-851.
61. Sarchielli P, Pini LA, Zanchin G, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006; 26: 257-265.
62. Loder E,. Triptan therapy in migraine. N Engl J Med. 2010; 363: 63-70.
63. Levy D, Jakubowski M, Burstein R,. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004; 101: 4274-4279.
64. Bartsch T, Knight YE, Goadsby PJ,. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004; 56: 371-381.
65. Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010; 641: 82-87.
66. Pytliak M, Vargova V, Mechirova V, Felsoci M,. Serotonin receptors-From molecular biology to clinical applications. Physiol Res. 2011; 60: 15-25.
67. Schurks M, Kurth T, Stude P, et al. G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007; 82: 396-401.
68. Durham PL, Masterson CG,. Two mechanisms involved in trigeminal CGRP release: Implications for migraine treatment. Headache. 2013; 53: 67-80.
69. Durham PL, Cady R,. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011; 51: 1573-1577.
70. Modi S, Lowder DM,. Medications for migraine prophylaxis. Am Fam Physician. 2006; 73: 72-78.
71. Pompili M, Serafini G, Innamorati M, et al. Patient outcome in migraine prophylaxis: The role of psychopharmacological agents. Patient Relat Outcome Meas. 2010; 1: 107-118.
72. Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A,. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009; 29: 423-429.
73. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH,. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004; 24: 735-739.
74. Vieira DS, Naffah-Mazzacoratti MG, Zukerman E, Senne Soares CA, Cavalheiro EA, Peres MF,. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache. 2007; 47: 842-847.
75. Vaccaro M, Riva C, Tremolizzo L, et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia. 2007; 27: 35-40.
76. Rozen T, Swidan SZ,. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007; 47: 1050-1055.
77. Harrington MG, Fonteh AN, Cowan RP, et al. Cerebrospinal fluid sodium increases in migraine. Headache. 2006; 46: 1128-1135.
78. Harrington MG, Salomon RM, Pogoda JM, et al. Cerebrospinal fluid sodium rhythms. Cerebrospinal Fluid Res. 2010; 7: 3.
79. Sarchielli P, Alberti A, Candeliere A, Floridi A, Capocchi G, Calabresi P,. Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia. 2006; 26: 409-415.
80. Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC,. Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia. 1995; 15: 489-493.
81. Fonteh AN, Chung R, Sharma TL, et al. Cerebrospinal fluid phospholipase C activity increases in migraine. Cephalalgia. 2011; 31: 456-462.
82. Valenzuela RF, Donoso MV, Mellado PA, Huidobro-Toro JP,. Migraine, but not subarachnoid hemorrhage, is associated with differentially increased NPY-like immunoreactivity in the CSF. J Neurol Sci. 2000; 173: 140-146.
83. Gibney ER, Nolan CM,. Epigenetics and gene expression. Heredity (Edinb). 2010; 105: 4-13.
84. Bonasio R, Tu S, Reinberg D,. Molecular signals of epigenetic states. Science. 2010; 330: 612-616.
85. Huang K, Fan G,. Epigenetic modifications in distinction: Histone versus DNA methylation in ESCs. Cell Stem Cell. 2011; 8: 604-605.
86. Feng J, Fouse S, Fan G,. Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res. 2007; 61: 58R-63R.
87. Uchida H, Ma L, Ueda H,. Epigenetic gene silencing underlies C-fiber dysfunctions in neuropathic pain. J Neurosci. 2010; 30: 4806-4814.
88. Montagna P,. The primary headaches: Genetics, epigenetics and a behavioural genetic model. J Headache Pain. 2008; 9: 57-69.
89. Park KY, Fletcher JR, Raddant AC, Russo AF,. Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia. Cephalalgia. 2011; 31: 614-624.
90. Nandha R, Singh H,. Renin angiotensin system: A novel target for migraine prophylaxis. Indian J Pharmacol. 2012; 44: 157-160.
91. Peroutka SJ, Wilhoit T, Jones K,. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997; 49: 201-206.
92. Kusumi M, Ishizaki K, Kowa H, et al. Glutathione S-transferase polymorphisms: Susceptibility to migraine without aura. Eur Neurol. 2003; 49: 218-222.
93. Mochi M, Cevoli S, Cortelli P, et al. A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta- hydroxylase genes. Neurol Sci. 2003; 23: 301-305.
94. Ates O, Kurt S, Altinisik J, Karaer H, Sezer S,. Genetic variations in tumor necrosis factor alpha, interleukin-10 genes, and migraine susceptibility. Pain Med. 2011; 12: 1464-1469.
95. Schurks M, Rist PM, Zee RY, Chasman DI, Kurth T,. Tumour necrosis factor gene polymorphisms and migraine: A systematic review and meta-analysis. Cephalalgia. 2011; 31: 1381-1404.
96. Samaan Z, Gaysina D, Cohen-Woods S, et al. Methylenetetrahydrofolate reductase gene variant (MTHFR C677T) and migraine: A case control study and meta-analysis. BMC Neurol. 2011; 11: 66.
97. Fernandez F, Colson N, Quinlan S, MacMillan J, Lea RA, Griffiths LR,. Association between migraine and a functional polymorphism at the dopamine beta-hydroxylase locus. Neurogenetics. 2009; 10: 199-208.
98. Lin JJ, Wang PJ, Chen CH, Yueh KC, Lin SZ, Harn HJ,. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta Neurol Taiwan. 2005; 14: 120-125.
99. Kowa H, Fusayasu E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett. 2005; 374: 129-131.
100. Paterna S, Di PP, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000; 43: 133-136.
101. Rainero I, Rubino E, Gallone S, et al. Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain. 2011; 12: 193-199.
102. Lemos C, Pereira-Monteiro J, Mendonca D, et al. Evidence of syntaxin 1A involvement in migraine susceptibility: A Portuguese study. Arch Neurol. 2010; 67: 422-427.
103. Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P,. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain. 2010; 11: 151-156.
104. Isobe C, Terayama Y,. A remarkable increase in total homocysteine concentrations in the CSF of migraine patients with aura. Headache. 2010; 50: 1561-1569.
105. Bo SH, Davidsen EM, Gulbrandsen P, et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia. 2009; 29: 365-372.
106. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid. Cephalalgia. 2008; 28: 714-722.
107. Castillo J, Martinez F, Suarez C, Naveiro J, Lema M, Noya M,. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia. 1996; 16: 56-61.